Asset Details
Do you wish to reserve the book?
Effects of hemoadsorption on plasma catecholamine levels: an in vitro study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of hemoadsorption on plasma catecholamine levels: an in vitro study
Do you wish to request the book?
Effects of hemoadsorption on plasma catecholamine levels: an in vitro study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of hemoadsorption on plasma catecholamine levels: an in vitro study
2026
Overview
Hemoadsorption with polystyrene-divinylbenzene (PS-DVB)-based adsorbents is explored as an adjunctive extracorporeal therapy in selected critically ill patients with dysregulated systemic inflammation. However, such therapy must not interfere with standard treatments, including antimicrobial therapy and hemodynamic stabilization with vasoactive drugs. As catecholamines are rarely quantified analytically in clinical practice, there are currently no studies reporting actual plasma levels during hemoadsorption. This in vitro study evaluated whether hemoadsorption with PS-DVB-based adsorbents alters plasma concentrations of epinephrine, norepinephrine, and dobutamine. Miniaturized PS-DVB adsorbers were used in 300-minute experiments; serial plasma samples were quantified, and apparent plasma clearance was derived from concentration-time data. Epinephrine and norepinephrine concentrations remained essentially unchanged over 300 min, with very low apparent plasma clearance (< 5 mL/min), indicating no meaningful removal under the tested conditions. By contrast, dobutamine demonstrated consistent, measurable clearance (approximately 5–15 mL/min), indicating non-negligible adsorption. Under these in vitro conditions, PS-DVB hemoadsorption did not materially remove epinephrine or norepinephrine but produced measurable removal of dobutamine. These findings are compatible with observational reports of reduced overall vasopressor requirements during hemoadsorption, while highlighting the potential for dobutamine underexposure. Future clinical studies should directly measure therapeutic plasma levels – particularly for dobutamine – during PS-DVB hemoadsorption and assess whether dosing adjustments are required to maintain intended inotropic effects without compromising safety.
